Results 241 to 250 of about 11,777 (278)
Some of the next articles are maybe not open access.
ChemInform Abstract: Asymmetric Synthesis of the Novel Antidepressant Rolipram
ChemInform, 1994AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
openaire +3 more sources
Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram
Pharmacology Biochemistry and Behavior, 1995The discriminative stimulus properties of the specific type IV phosphodiesterase inhibitor, rolipram, and its two stereoisomers were assessed using standard two-lever drug discrimination procedures in which responding on the appropriate lever was reinforced on a FR10 schedule.
David N. Stephens +3 more
openaire +3 more sources
Rolipram versus nortriptyline in gerontopsychiatric inpatients with major depression
Nordic Journal of Psychiatry, 1992To define the therapeutic profile of the new putative antidepressant rolipram, a double-blind (double-dummy) study with 0.5 mg rolipram versus 25 mg nortriptyline three times daily was conducted in hospitalized gerontopsychiatric inpatients with major depression. During both therapies, improvement was achieved compared with base line. However, the rate
B. Mejer-Nielsen +8 more
openaire +2 more sources
Results of a Phase II Study of the Antidepressant Effect of Rolipram
Pharmacopsychiatry, 1984The antidepressant effect of rolipram, believed to be based on a new mechanism of action, was investigated in an open phase II study in 10 depressive patients, most of whom had been refractory to previous antidepressant therapy. Five patients displayed a good to very good improvement of their depressive condition.
B Pflug +3 more
openaire +2 more sources
International Journal of Neuropsychopharmacology, 2014
Inhibition of phosphodiesterase-4 (PDE4), an enzyme that specifically hydrolyzes cyclic adenosine monophosphate (cAMP) increases intracellular cAMP/cAMP-response element binding protein (CREB) signaling.
M. Lai +7 more
semanticscholar +1 more source
Inhibition of phosphodiesterase-4 (PDE4), an enzyme that specifically hydrolyzes cyclic adenosine monophosphate (cAMP) increases intracellular cAMP/cAMP-response element binding protein (CREB) signaling.
M. Lai +7 more
semanticscholar +1 more source
Mapping of second messenger and rolipram receptors in mammalian brain
Brain Research Bulletin, 1992Autoradiographic localizations of major second messengers and a selective cyclic adenosine monophosphate (cyclic-AMP) phosphodiesterase in the brain were visualized in the gerbil and the rat using receptor autoradiography. [3H]Phorbol 12,13-dibutyrate (PDBu), [3H]inositol 1,4,5-trisphosphate (IP3), [3H]forskolin, [3H]cyclic-AMP, and [3H]rolipram were ...
Hiroyuki Kato +2 more
openaire +3 more sources
Enhancement of the relative uptake of18F-FDG in mouse fibrosarcoma by rolipram
Annals of Nuclear Medicine, 2002The effect of rolipram, a selective phosphodiesterase type 4 inhibitor, on the uptake of 18F-fluorodeoxyglucose (18F-FDG) in tumor tissue was examined in mice transplanted with NFSa fibrosarcoma. The uptake indexes of 18F-FDG in the heart, skeletal muscle and brain remarkably decreased after treatment with 3 mg/kg of rolipram (heart: 13%, skeletal ...
Rie Hosoi +6 more
openaire +3 more sources
Journal of Cardiovascular Pharmacology, 1990
The involvement of rolipram-sensitive phosphodiesterase (PDE IV) in regulation of cardiac contraction was investigated by studying the effect of selective inhibitors (rolipram, denbufylline, Ro 20-1724) on guinea pig left atria contraction. In contrast to milrinone and SK&F 94120 (inhibitors of the cyclic GMP-inhibited PDE, PDE III), (+/-)-rolipram and
Bernard Muller +2 more
openaire +3 more sources
The involvement of rolipram-sensitive phosphodiesterase (PDE IV) in regulation of cardiac contraction was investigated by studying the effect of selective inhibitors (rolipram, denbufylline, Ro 20-1724) on guinea pig left atria contraction. In contrast to milrinone and SK&F 94120 (inhibitors of the cyclic GMP-inhibited PDE, PDE III), (+/-)-rolipram and
Bernard Muller +2 more
openaire +3 more sources
Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in parkinson's disease
Pharmacological Research Communications, 1983The effects of Rolipram, a new phosphodiesterase inhibitor, were assessed in a double-blind trial versus placebo in 10 patients with Parkinson's disease already under treatment. Contrary to previous findings with specific phosphodiesterase inhibitors, with Rolipram (at the dose of 3 mg per day), no significant deterioration of the therapeutic action of
G. Meco +5 more
openaire +3 more sources
Journal of Sexual Medicine, 2014
INTRODUCTION Phosphodiesterase type 5 (PDE5) inhibitors act as effective drugs for the treatment of lower urinary tract symptom (LUTS). There is a poor information, however, about the role of the PDE4 inhibitors on the bladder outflow region ...
A. S. Ribeiro +12 more
semanticscholar +1 more source
INTRODUCTION Phosphodiesterase type 5 (PDE5) inhibitors act as effective drugs for the treatment of lower urinary tract symptom (LUTS). There is a poor information, however, about the role of the PDE4 inhibitors on the bladder outflow region ...
A. S. Ribeiro +12 more
semanticscholar +1 more source